

CIN: L24239TG1991PLC012264

Plot Nos.10 To 14 And 16 To 20, Apiic, Industrial Estate, Chityal, Gop Alaipalli Na, Telangana -508254, India

e-mail: admin.hyd@vistapharmaceuticals.com www.vistapharmaceuticals.com

Hyderabad, 06th September, 2023.

To,
The General Manager,
Listing Department,
BSE Limited,
P.J. Towers,
Dalal Street Fort,
Mumbai-400001.

Dear Sir/Ma'am,

Sub: Outcome of Board Meeting - Regulation 30

Ref: Company Scrip Code: 524711

With reference to the subject cited, it is hereby informed that the Board of Directors of the Company at its Meeting held on Wednesday, 06th September, 2023 at 12:00 PM and ended at 12:30 P.M at the corporate office of the Company *inter-alia* considered and approved the following:

- 1. Considered and approved the draft Notice for the 32nd Annual General Meeting of the Members of the Company.
- 2. To issue of up to 1,73,54,676 equity shares of the company having face value of 02/- each ("equity shares"), proposed to be issued at RS. 12.96/- each (including premium of Rs. 10.96/- per equity shares) on a preferential basis ("preferential issue") in accordance with Chapter V of the Securities And Exchange Board Of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 ("SEBI ICDR Regulations"), as amended, and other applicable laws, subject to the approval of the members of the company and such regulatory/ statutory authorities as may be applicable.



CIN: L24239TG1991PLC012264

Plot Nos.10 To 14 And 16 To 20, Apiic, Industrial Estate, Chityal, Gop Alaipalli Na, Telangana -508254, India

e-mail: admin.hyd@vistapharmaceuticals.com www.vistapharmaceuticals.com

- 3. The board has approved 31st August, 2023 as relevant date, being 30 days prior to the date of passing of resolution by the members at the Annual General Meeting in relation to issue of shares on preferential basis.
- 4. Considered and approved to the Increase the Authorized Share Capital of the Company from Rs.15 Crore to Rs.20 Crore.
- 5. Considered and approved to the alteration of Capital Clause of the Memorandum of Association of the Company.
- 6. Considered and approved to the alteration of Article 4 of Article of Association of the Company.
- 7. Considered and approved the Valuation Report received from the Registered Valuer.

Kindly take the same on record and acknowledge the receipt of the same.

Thanking You,

For Vista Pharmaceuticals Limited

DHANANJAYA ALLI

WHOLETIME DIRECTOR

DIN: 0061090



CIN: L24239TG1991PLC012264

Plot Nos.10 To 14 And 16 To 20, Apiic, Industrial Estate, Chityal, Gop Alaipalli Na, Telangana -508254, India

e-mail: admin.hyd@vistapharmaceuticals.com www.vistapharmaceuticals.com

Annexure-I

The details as required to be disclosed under regulation 30 read with SEBI circular dated September 09, 2015:

Issuance of Securities:

issuance of Securities.					
S.No	Particulars	Details of Securities			
1	Type of securities proposed to be issued	Equity Shares			
	(viz. Equity shares, convertibles, etc.				
2	Type of issuance (Further Public Offering, Rights Issue, Depository Receipts (ADR/GDR), Qualified Institutions Placement, Preferential Allotment etc.)	Preferential issue in accordance with Chapter V of the Securities And Exchange Board Of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 ("SEBI ICDR Regulations"), as amended, and other applicable laws.			
3	Total Number of securities proposed to be issued or the total amount for which the securities will be issued.	Up to 1,73,54,676 equity shares at a price of Rs. 12.96/- each (including premium of Rs. 10.96/- per equity shares) per equity share in cash for an aggregate consideration of upto Rs. 22,49,16,600/			
IN CASE OF PREFERENTIAL ISSUE THE LISTED ENTITY SHALL DISCLOSE THE FOLLOWING ADDITIONAL DETAILS TO THE STOCK EXCHANGE(S):					
1	Name of the investors	Enclosed as Annexure II			
2	Post allotment of securities- Outcome of the subscription, issue price/allotted price (in case of convertible securities), Number of Investors;	The issue and allotment of equity shares is subject to the approval of the members of the company by passing of Special Resolution.			
3	In case of convertibles- Intimation on conversion of securities or on lapse of the tenure the instrument;	N.A			



CIN: L24239TG1991PLC012264

Plot Nos.10 To 14 And 16 To 20, Apiic, Industrial Estate, Chityal, Gop Alaipalli Na, Telangana -508254, India

e-mail: admin.hyd@vistapharmaceuticals.com www.vistapharmaceuticals.com

Annexure II

Sr. No	Name of the Investors	Category (Promoter/ Non-Promoter)	No. of Equity Shares under Preferential Issue
1	Pranali bangad	Non-Promoter	8,25,000
2	Anjana bangad	Non-Promoter	8,25,000
3	Sheela bangad	Non-Promoter	8,25,000
4	Anuradha bangad	Non-Promoter	8,25,000
5	Sushma bangad	Non-Promoter	8,25,000
6	Aditya bangad HUF	Non-Promoter	8,25,000
7	Krishna Bangad	Non-Promoter	8,25,000
8	Vaibhav bangad Huf	Non-Promoter	8,25,000
9	vikas Bangad	Non-Promoter	8,25,000
10	Usha devi bangad	Non-Promoter	7,49,600
11	Chenamaneni Sushmitha	Non-Promoter	40,87,300
12	Chenamaneni padmaja	Non-Promoter	40,87,300
13	komal sharma	Non-Promoter	5,00,000
14	Chaitanya Pavuluri	Non-Promoter	1,68,492
15	TV Muralidhar	Non-Promoter	1,68,492
16	Sivaprakasam Sivakumar	Non-Promoter	1,68,492
	Total		1,73,54,676